Initiation and Single Dispensing in Cardiovascular and Insulin Medications: Prevalence and Explanatory Factors

dc.contributor.authorVilaplana Carnerero, Carles
dc.contributor.authorAznar Lou, Ignacio
dc.contributor.authorPeñarrubia María, María Teresa
dc.contributor.authorSerrano Blanco, Antoni
dc.contributor.authorFernández-Vergel, Rita
dc.contributor.authorPetitbò-Antúnez, Dolors
dc.contributor.authorGil Girbau, Mª Montserrat
dc.contributor.authorMarch Pujol, Marian
dc.contributor.authorMendive, Juan Manuel
dc.contributor.authorSánchez-Viñas, Alba
dc.contributor.authorCarbonell-Duacastella, Cristina
dc.contributor.authorRubio Valera, Maria
dc.date.accessioned2022-03-04T12:45:19Z
dc.date.available2022-03-04T12:45:19Z
dc.date.issued2020-05-12
dc.date.updated2022-03-04T12:45:19Z
dc.description.abstract: Background: Adherence problems have negative effects on health, but there is little information on the magnitude of non-initiation and single dispensing. Objective: The aim of this study was to estimate the prevalence of non-initiation and single dispensation and identify associated predictive factors for the main treatments prescribed in Primary Care (PC) for cardiovascular disease (CVD) and diabetes. Methods: Cohort study with real-world data. Patients who received a first prescription (2013-2014) for insulins, platelet aggregation inhibitors, angiotensin-converting enzyme inhibitors (ACEI) or statins in Catalan PC were included. The prevalence of non-initiation and single dispensation was calculated. Factors that explained these behaviours were explored. Results: At three months, between 5.7% (ACEI) and 9.1% (antiplatelets) of patients did not initiate their treatment and between 10.6% (statins) and 18.4% (ACEI) filled a single prescription. Body mass index, previous CVD, place of origin and having a substitute prescriber, among others, influenced the risk of non-initiation and single dispensation. Conclusions: The prevalence of non-initiation and single dispensation of CVD medications and insulin prescribed in PC in is high. Patient and health-system factors, such as place of origin and type of prescriber, should be taken into consideration when prescribing new medications for CVD and diabetes.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec715708
dc.identifier.issn1661-7827
dc.identifier.urihttps://hdl.handle.net/2445/183766
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijerph17103358
dc.relation.ispartofInternational Journal of Environmental Research and Public Health, 2020, vol. 17, num. 10, p. 3358
dc.relation.urihttps://doi.org/10.3390/ijerph17103358
dc.rightscc-by (c) Vilaplana Carnerero, Carles et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties cardiovasculars
dc.subject.classificationInsulina
dc.subject.otherCardiovascular diseases
dc.subject.otherInsulin
dc.titleInitiation and Single Dispensing in Cardiovascular and Insulin Medications: Prevalence and Explanatory Factors
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
715708.pdf
Mida:
810.21 KB
Format:
Adobe Portable Document Format